-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study . Lancet Haematol 2020 ; 7 : e456 – 468 . 32359506 40. Stadtmauer EA , Pasquini MC , Blackwell
Search Results
Defining and Managing High-Risk Multiple Myeloma: Current Concepts
Luciano J. Costa and Saad Z. Usmani
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
Featured Updates to the NCCN Guidelines
Daniel A. Pollyea, Dale Bixby, Alexander Perl, Vijaya Raj Bhatt, Jessica K. Altman, Frederick R. Appelbaum, Marcos de Lima, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Jadee Neff, Reza Nejati, Rebecca Olin, Mary-Elizabeth Percival, Thomas Prebet, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi-Kashani, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Kendra Sweet, Pankit Vachhani, Matthew Wieduwilt, Kristina M. Gregory, Ndiya Ogba, and Martin S. Tallman
divided into initial remission-induction chemotherapy, postremission or consolidation therapy, and, recently, maintenance therapy, using oral azacitidine for patients who are unable to complete intensive curative therapy. 5 Although obtaining a remission
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018
Steven M. Horwitz, Stephen M. Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Michael Choi, Mark W. Clemens, Ahmet Dogan, John P. Greer, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Youn H. Kim, Matthew A. Lunning, Amitkumar Mehta, Neha Mehta-Shah, Yahurio Oki, Elise A. Olsen, Barbara Pro, Saurabh A. Rajguru, Satish Shanbhag, Andrei Shustov, Lubomir Sokol, Pallawi Torka, Ryan Wilcox, Basem William, Jasmine Zain, Mary A. Dwyer, and Hema Sundar
(HCT) has been evaluated as a consolidation therapy for patients with early- and advanced-stage ENKL responding to primary therapy. In retrospective analyses, disease status at the time of transplant was the most important prognostic factor for OS and
Variation in Use of High-Cost Technologies for Palliative Radiation Therapy by Radiation Oncologists
Aileen B. Chen, Jiangong Niu, Angel M. Cronin, Ya-Chen Tina Shih, Sharon Giordano, and Deborah Schrag
, . Palliative radiotherapy tailored to life expectancy in end-stage cancer patients: reality or myth? Cancer 2010 ; 116 : 3251 – 3256 . 10.1002/cncr.25112 5. Gomez DR , Tang C , Zhang J , . Local consolidative therapy vs
Individualized Approach to Management of Light Chain Amyloidosis
Giovanni Palladini and Paolo Milani
-based therapy followed by autologous stem cell transplant in AL amyloidosis . Blood Adv 2020 ; 4 : 4175 – 4179 . 32886751 22. Al Saleh AS , Sidiqi MH , Sidana S , Impact of consolidation therapy post autologous stem cell transplant in patients
Hodgkin Lymphoma, Version 2.2015
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Nadia Khan, David G. Maloney, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Matthew Poppe, Rachel Rabinovitch, Stuart Seropian, Christina Tsien, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, and Hema Sundar
However, the use of consolidative RT was effective for patients with a PET-positive partial remission, because the 4-year PFS rate in this group was 86.2%. Two recent European trials evaluated the role of HDT/ASCR as a consolidative therapy for patients
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Steven M. Horwitz, Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Jonathan Brammer, Mark W. Clemens, Ahmet Dogan, Francine Foss, Paola Ghione, Aaron M. Goodman, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Allison Jones, Avyakta Kallam, Youn H. Kim, Kiran Kumar, Neha Mehta-Shah, Elise A. Olsen, Saurabh A. Rajguru, Sima Rozati, Jonathan Said, Aaron Shaver, Lauren Shea, Michi M. Shinohara, Lubomir Sokol, Carlos Torres-Cabala, Ryan Wilcox, Peggy Wu, Jasmine Zain, Mary Dwyer, and Hema Sundar
-Line Consolidation Therapy Several nonrandomized prospective studies 59 – 70 and retrospective analyses 28 , 71 – 74 have reported favorable outcomes in patients with PTCL undergoing first-line consolidation with high-dose therapy followed by autologous stem cell
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Patrick A. Brown, Bijal Shah, Anjali Advani, Patricia Aoun, Michael W. Boyer, Patrick W. Burke, Daniel J. DeAngelo, Shira Dinner, Amir T. Fathi, Jordan Gauthier, Nitin Jain, Suzanne Kirby, Michaela Liedtke, Mark Litzow, Aaron Logan, Selina Luger, Lori J. Maness, Stephanie Massaro, Ryan J. Mattison, William May, Olalekan Oluwole, Jae Park, Amanda Przespolewski, Sravanti Rangaraju, Jeffrey E. Rubnitz, Geoffrey L. Uy, Madhuri Vusirikala, Matthew Wieduwilt, Beth Lynn, Ryan A. Berardi, Deborah A. Freedman-Cass, and Mallory Campbell
-specific factors may have prognostic significance in patients with ALL. In particular, patient age, WBC count, immunophenotypic/cytogenetic subtype, presence of CNS disease, and response to induction/consolidation therapy have been identified as important factors
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Jeffrey Crawford, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A. Griffiths, Shannon Hough, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L. Burns, and Lenora Pluchino
-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group . Blood 1997 ; 90 : 4710 – 4718 . 88. Kroschinsky F Holig K
The Management of Patients With Stage IIIA Non–Small Cell Lung Cancer With N2 Mediastinal Node Involvement
Renato G. Martins, Thomas A. D’Amico, Billy W. Loo Jr, Mary Pinder-Schenck, Hossein Borghaei, Jamie E. Chaft, Apar Kishor P. Ganti, Feng-Ming (Spring) Kong, Mark G. Kris, Inga T. Lennes, and Douglas E. Wood
. Eur J Cardiothorac Surg 2009 ; 35 : 718 – 723 . 52 Edelman MJ Paulus R Suntharalingam M . RTOG 0229: a phase II trial of concurrent chemotherapy and full dose radiotherapy followed by surgical resection and consolidative therapy for
